炎症性肠病女性妊娠期使用生物制剂与婴儿感染风险的系统评价与Meta分析
该系统评价与Meta分析检索截至2020年6月的多个数据库,纳入9项研究、8013例炎症性肠病孕妇及8490例婴儿,评估妊娠期生物制剂暴露与婴儿感染风险的关联。结果显示生物制剂未增加婴儿总体感染风险(OR 0.91,95%CI 0.73-1.14),但亚组分析中与婴儿上呼吸道感染风险增加相关(OR 1.57,95%CI 1.02-2.40)。
要点
- 妊娠期使用生物制剂未增加婴儿总体感染风险(OR 0.91,95%CI 0.73-1.14)。
- 亚组分析显示生物制剂与婴儿上呼吸道感染风险增加相关(OR 1.57,95%CI 1.02-2.40)。
- 生物制剂与婴儿抗生素使用或感染相关住院风险无显著关联。
核心结论
- 炎症性肠病女性妊娠期使用生物制剂与婴儿总体感染风险或需要抗生素或住院的严重感染无关,但与上呼吸道感染风险增加相关。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、Embase、Scopus、Web of Science和Cochrane对照试验中心注册库(CENTRAL)自建库至2020年6月。
- 纳入9项研究,共8013例炎症性肠病女性(5212例克罗恩病,2801例溃疡性结肠炎),其分娩的8490例婴儿。
- 采用随机效应模型合并和分析结局的比值比(OR)。
主要发现
- 妊娠期使用生物制剂与婴儿总体感染风险增加无关(OR 0.91,95%CI 0.73-1.14,I²=30%)。
- 在感染类型亚组分析中,生物制剂使用与婴儿上呼吸道感染风险增加相关(OR 1.57,95%CI 1.02-2.40,I²=4%)。
- 妊娠期使用生物制剂与婴儿抗生素使用无关(OR 0.91,95%CI 0.73-1.14,I²=30%)。
- 妊娠期使用生物制剂与婴儿感染相关住院无关(OR 1.33,95%CI 0.95-1.86,I²=26%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Biologics, such as tumor necrosis factor inhibitors, anti-integrins and anticytokines, are therapies for inflammatory bowel disease (IBD) that may increase the risk of infection. Most biologics undergo placental transfer during pregnancy and persist at detectable concentrations in exposed infants. Whether this is associated with an increased risk of infantile infections is controversial. We performed a systematic review and meta-analysis evaluating the risk of infantile infections after in utero exposure to biologics used to treat IBD. METHODS: We searched PubMed, Embase, Scopus, Web of Science, and CENTRAL from inception to June 2020 to evaluate the association of biologic therapy during pregnancy in women with IBD and risk of infantile infections. Odds ratios of outcomes were pooled and analyzed using a random effects model. RESULTS: Nine studies met the inclusion criteria comprising 8,013 women with IBD (5,212 Crohn's disease, 2,801 ulcerative colitis) who gave birth to 8,490 infants. Biologic use during pregnancy was not associated with an increased risk of all infantile infections (odds ratio [OR] 0.91, 95% confidence interval [CI] 0.73-1.14, I2 = 30%). In a subgroup analysis for the type of infection, biologic use was associated with increased infantile upper respiratory infections (OR 1.57, 95% CI 1.02-2.40, I2 = 4%). Biologic use during pregnancy was not associated with infantile antibiotic use (OR 0.91, 95% CI 0.73-1.14, I2 = 30%) or infection-related hospitalizations (OR 1.33, 95% CI 0.95-1.86, I2 = 26%). DISCUSSION: Biologics use during pregnancy in women with IBD is not associated with the overall risk of infantile infections or serious infections requiring antibiotics or hospitalizations but is associated with an increased risk of upper respiratory infections.
引用
- Gubatan J, Nielsen OH, Levitte S, et al. Biologics During Pregnancy in Women With Inflammatory Bowel Disease and Risk of Infantile Infections: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2021. PMID: 33110017. doi:10.14309/ajg.0000000000000910
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。